Orthofix Medical Inc (OFIX)

$11.76

+0.39

(+3.43%)▲

Market is closed - opens 8 PM, 11 Dec 2023

Insights on Orthofix Medical Inc

  • Decreasing Revenue

    Revenue is down for the last 2 quarters, 187.01M → 184.00M (in $), with an average decrease of 1.6% per quarter

  • Increasing Net Profit

    Netprofit is up for the last 3 quarters, -60.93M → -28.85M (in $), with an average increase of 45.6% per quarter

  • Vs BSX

    In the last 1 year, Boston Scientific Corp. has given 18.9% return, outperforming this stock by 61.1%

  • Vs BSX

    In the last 3 years, Boston Scientific Corp. has given 61.0% return, outperforming this stock by 130.4%

Performance

  • $11.24
    $11.89
    $11.76
    downward going graph

    4.42%

    Downside

    Day's Volatility :5.43%

    Upside

    1.05%

    downward going graph
  • $9.57
    $23.19
    $11.76
    downward going graph

    18.62%

    Downside

    52 Weeks Volatility :58.73%

    Upside

    49.29%

    downward going graph

Returns

PeriodOrthofix Medical IncSector (Health Care)Index (Russel 2000)
3 Months
-36.88%
0.0%
0.0%
6 Months
-38.3%
1.3%
0.0%
1 Year
-42.18%
-4.3%
-1.5%
3 Years
-69.38%
17.6%
-7.0%

Highlights

Market Capitalization
408.7M
Book Value
$16.75
Dividend Share
0.0
Dividend Yield
10.85%
Earnings Per Share (EPS)
-3.88
PEG Ratio
0.33
Wall Street Target Price
18.0
Profit Margin
-20.39%
Operating Margin TTM
-8.51%
Return On Assets TTM
-7.09%
Return On Equity TTM
-28.72%
Revenue TTM
668.5M
Revenue Per Share TTM
20.58
Quarterly Revenue Growth YOY
61.4%
Gross Profit TTM
337.2M
EBITDA
-25.1M
Diluted Eps TTM
-3.88
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
-0.14
EPS Estimate Next Year
-0.13
EPS Estimate Current Quarter
-0.21
EPS Estimate Next Quarter
-0.25

Analyst Recommendation

Buy
    54%Buy
    45%Hold
    0
    0%Sell
Based on 11 Wall street analysts offering stock ratings for Orthofix Medical Inc(by analysts ranked 0 to 5 stars)
Based on 11 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
6
6
8
Hold
5
4
2
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 53.06%

Current $11.76
Target $18.00

Company Financials

FY17Y/Y Change
Revenue
433.8M
↑ 5.87%
Net Income
6.2M
↑ 103.63%
Net Profit Margin
1.43%
↑ 0.68%
FY18Y/Y Change
Revenue
453.0M
↑ 4.43%
Net Income
13.8M
↑ 121.93%
Net Profit Margin
3.05%
↑ 1.62%
FY19Y/Y Change
Revenue
460.0M
↑ 1.53%
Net Income
-28.5M
↓ 306.08%
Net Profit Margin
-6.19%
↓ 9.24%
FY20Y/Y Change
Revenue
406.6M
↓ 11.61%
Net Income
2.5M
↓ 108.84%
Net Profit Margin
0.62%
↑ 6.81%
FY21Y/Y Change
Revenue
464.5M
↑ 14.25%
Net Income
-38.4M
↓ 1624.79%
Net Profit Margin
-8.26%
↓ 8.88%
FY22Y/Y Change
Revenue
460.7M
↓ 0.81%
Net Income
-19.7M
↓ 48.54%
Net Profit Margin
-4.29%
↑ 3.97%
Q2 FY22Q/Q Change
Revenue
118.1M
↑ 10.95%
Net Income
2.5M
↓ 155.81%
Net Profit Margin
2.11%
↑ 6.3%
Q3 FY22Q/Q Change
Revenue
114.0M
↓ 3.45%
Net Income
-10.7M
↓ 530.53%
Net Profit Margin
-9.4%
↓ 11.51%
Q4 FY22Q/Q Change
Revenue
122.2M
↑ 7.22%
Net Income
-7.1M
↓ 34.1%
Net Profit Margin
-5.78%
↑ 3.62%
Q1 FY23Q/Q Change
Revenue
175.2M
↑ 43.34%
Net Income
-60.9M
↑ 762.9%
Net Profit Margin
-34.78%
↓ 29.0%
Q2 FY23Q/Q Change
Revenue
187.0M
↑ 6.74%
Net Income
-39.4M
↓ 35.3%
Net Profit Margin
-21.08%
↑ 13.7%
Q3 FY23Q/Q Change
Revenue
184.0M
↓ 1.61%
Net Income
-28.9M
↓ 26.81%
Net Profit Margin
-15.68%
↑ 5.4%
FY17Y/Y Change
Total Assets
405.4M
↑ 8.94%
Total Liabilities
108.7M
↑ 0.11%
FY18Y/Y Change
Total Assets
466.6M
↑ 15.12%
Total Liabilities
131.2M
↑ 20.69%
FY19Y/Y Change
Total Assets
495.6M
↑ 6.21%
Total Liabilities
168.0M
↑ 28.0%
FY20Y/Y Change
Total Assets
525.9M
↑ 6.1%
Total Liabilities
169.0M
↑ 0.6%
FY21Y/Y Change
Total Assets
476.6M
↓ 9.36%
Total Liabilities
139.7M
↓ 17.34%
FY22Y/Y Change
Total Assets
458.6M
↓ 3.78%
Total Liabilities
121.8M
↓ 12.83%
Q2 FY22Q/Q Change
Total Assets
461.7M
↓ 0.07%
Total Liabilities
119.7M
↓ 5.31%
Q3 FY22Q/Q Change
Total Assets
449.7M
↓ 2.6%
Total Liabilities
116.1M
↓ 3.0%
Q4 FY22Q/Q Change
Total Assets
458.6M
↑ 1.99%
Total Liabilities
121.8M
↑ 4.86%
Q1 FY23Q/Q Change
Total Assets
917.1M
↑ 99.97%
Total Liabilities
253.0M
↑ 107.75%
Q2 FY23Q/Q Change
Total Assets
901.3M
↓ 1.73%
Total Liabilities
261.3M
↑ 3.29%
Q3 FY23Q/Q Change
Total Assets
905.7M
↑ 0.48%
Total Liabilities
290.2M
↑ 11.05%
FY17Y/Y Change
Operating Cash Flow
53.3M
↑ 19.31%
Investing Cash Flow
-16.5M
↓ 24.94%
Financing Cash Flow
3.5M
↓ 107.67%
FY18Y/Y Change
Operating Cash Flow
49.9M
↓ 6.42%
Investing Cash Flow
-61.0M
↑ 270.27%
Financing Cash Flow
3.0M
↓ 15.4%
FY19Y/Y Change
Operating Cash Flow
32.0M
↓ 35.83%
Investing Cash Flow
-22.9M
↓ 62.42%
Financing Cash Flow
-10.7M
↓ 457.1%
FY20Y/Y Change
Operating Cash Flow
74.3M
↑ 131.86%
Investing Cash Flow
-52.3M
↑ 128.29%
Financing Cash Flow
3.2M
↓ 130.36%
FY21Y/Y Change
Operating Cash Flow
18.5M
↓ 75.13%
Investing Cash Flow
-23.0M
↓ 56.03%
Financing Cash Flow
-3.6M
↓ 211.59%
FY22Y/Y Change
Operating Cash Flow
-11.5M
↓ 162.45%
Investing Cash Flow
-24.5M
↑ 6.61%
Financing Cash Flow
-78.0K
↓ 97.85%
Q2 FY22Q/Q Change
Operating Cash Flow
-4.9M
↓ 36.27%
Investing Cash Flow
-7.5M
↑ 32.24%
Financing Cash Flow
909.0K
↓ 140.71%
Q3 FY22Q/Q Change
Operating Cash Flow
-1.3M
↓ 74.27%
Investing Cash Flow
-5.5M
↓ 26.97%
Financing Cash Flow
-252.0K
↓ 127.72%
Q4 FY22Q/Q Change
Operating Cash Flow
2.3M
↓ 285.76%
Investing Cash Flow
-5.9M
↑ 7.8%
Financing Cash Flow
1.5M
↓ 694.44%
Q1 FY23Q/Q Change
Operating Cash Flow
-34.0M
↓ 1548.89%
Investing Cash Flow
17.1M
↓ 389.56%
Financing Cash Flow
16.0M
↑ 966.96%
Q2 FY23Q/Q Change
Operating Cash Flow
-5.5M
↓ 83.79%
Investing Cash Flow
-12.8M
↓ 175.04%
Financing Cash Flow
5.8M
↓ 63.66%

Technicals Summary

Sell

Neutral

Buy

Orthofix Medical Inc is currently in a favorable trading position ( BUY ) according to technical analysis indicators.

More on Technical Analysis

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Orthofix Medical Inc
Orthofix Medical Inc
10.63%
-38.3%
-42.18%
-69.38%
-79.18%
Stryker Corporation
Stryker Corporation
6.74%
3.01%
18.18%
22.54%
68.85%
Dexcom, Inc.
Dexcom, Inc.
26.59%
-5.93%
0.44%
40.34%
279.0%
Boston Scientific Corp.
Boston Scientific Corp.
6.84%
7.16%
18.86%
61.0%
52.01%
Abbott Laboratories
Abbott Laboratories
11.72%
2.77%
-2.79%
-1.7%
47.36%
Medtronic Plc
Medtronic Plc
13.21%
-5.23%
0.97%
-29.75%
-16.89%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Orthofix Medical Inc
Orthofix Medical Inc
NA
NA
0.33
-0.14
-0.29
-0.07
0.11
16.75
Stryker Corporation
Stryker Corporation
44.25
44.25
2.89
10.41
0.15
0.07
0.01
47.13
Dexcom, Inc.
Dexcom, Inc.
128.52
128.52
2.39
1.43
0.18
0.06
0.0
5.87
Boston Scientific Corp.
Boston Scientific Corp.
68.46
68.46
1.75
2.01
0.07
0.04
0.02
12.89
Abbott Laboratories
Abbott Laboratories
35.67
35.67
25.14
4.44
0.14
0.06
0.02
21.59
Medtronic Plc
Medtronic Plc
25.97
25.97
1.61
5.28
0.08
0.04
0.03
38.69
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Orthofix Medical Inc
Orthofix Medical Inc
Buy
$408.7M
-79.18%
NA
-20.39%
Stryker Corporation
Stryker Corporation
Buy
$113.1B
68.85%
44.25
13.0%
Dexcom, Inc.
Dexcom, Inc.
Buy
$45.1B
279.0%
128.52
11.08%
Boston Scientific Corp.
Boston Scientific Corp.
Buy
$82.2B
52.01%
68.46
8.93%
Abbott Laboratories
Abbott Laboratories
Buy
$182.1B
47.36%
35.67
12.92%
Medtronic Plc
Medtronic Plc
Buy
$106.4B
-16.89%
25.97
12.84%

Institutional Holdings

  • BlackRock Inc

    16.23%

  • Rubric Capital Management LP

    9.35%

  • Armistice Capital, LLC

    8.07%

  • Vanguard Group Inc

    6.76%

  • First Light Asset Management, LLC

    5.04%

  • State Street Corporation

    4.08%

Corporate Announcements

  • Orthofix Medical Inc Earnings

    Orthofix Medical Inc’s price-to-earnings ratio stands at None

    Read More

Company Information

orthofix international began in a small farmhouse in verona italy in 1980 when orthopedic researcher giovanni de bastiani recognized the bone’s natural repair capability, a concept he called “dynamization” and with that in mind, he created the first external fixation device. today, orthofix has grown to more than 900 employees with locations in the u.s., italy, germany, france, the uk, brazil, australia and puerto rico. our products help patients in 70 countries around the world. the company is comprised of four strategic business units; biostim, biologics, extremity fixation and spine fixation. our products are widely distributed via the company's sales representatives, distributors and subsidiaries. at orthofix we are committed to clinical research and driven by new product introductions. we are proud of our strong partnerships with organizations such as the texas scottish rite hospital for children in dallas and the musculoskeletal transplant foundation. we take pride in developing

Organization
Orthofix Medical Inc
Employees
1092
CEO
Mr. Jon C. Serbousek
Industry
Health Technology

Discover More

FAQs